NCT07089706View on ClinicalTrials.gov

A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations

PHASE4RecruitingINTERVENTIONAL
Enrollment

832

Participants

Timeline

Start Date

July 21, 2025

Primary Completion Date

May 11, 2026

Study Completion Date

May 11, 2026

Conditions
COVID-19
Interventions
BIOLOGICAL

mRNA-1283.251 Variant-containing Formulation

Sterile liquid for injection

Trial Locations (5)

30329

RECRUITING

DelRicht Research-Atlanta, Atlanta

39503

RECRUITING

DelRicht Research-Gulfport, Gulfport

70115

RECRUITING

DelRicht Research-New Orleans, New Orleans

70769

RECRUITING

DelRicht Research-Baton Rouge, Baton Rouge

74133

RECRUITING

DelRicht Research-Tulsa, Tulsa

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY